Skip to main content
OpenTrials
Active, not recruiting

NCT Number: NCT07814170

A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece

This clinical trial aims to determine whether a manualised group intervention for people with blood cancers can help them experience positive psychological changes following their diagnosis, known as post-traumatic growth. Participants receiving the intervention will be compared with those receiving usual care and placed on a waiting list. Participants will be randomly allocated to either the group intervention or the usual care/waiting-list group. The study will also explore how this intervention could be implemented within the Greek healthcare system. The study aims to answer the following main questions: (1) Does this psychological group intervention increase post-traumatic growth in people with blood cancers? (2) Does this intervention improve other outcomes, including anxiety, depression, quality of life, psychological well-being, cognitive functioning, distress, illness understanding and routine blood markers? Participants will: (1) Attend nine weekly face-to-face group sessions in Greek, each lasting approximately two hours, with other people living with blood cancers. (2) Receive a detailed manual/workbook covering the session content and be encouraged to use it between sessions. (3) Have the opportunity to participate in an optional outdoor activity of their choice. (4) Complete questionnaires and a brief cognitive assessment before and after the intervention, together with other assessments as required. Participation is voluntary and free of charge. Some participants may experience mild emotional discomfort when discussing their experiences; however, psychological support will be available if needed. The findings will help researchers determine whether this group intervention can support people living with blood cancers and inform the future implementation of similar interventions within the Greek healthcare system.

Active, not recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Blood Cancers Acute Lymphoid Leukemia (ALL) Anxiety Disorders Behavior Behavioral Symptoms Blood Protein Disorders Bone Marrow Diseases Bone Marrow Transplant Cardiovascular Diseases Chronic Disease Chronic Myeloid Leukemia (CML) Depression Disease Attributes Hematologic Diseases Hematologic Neoplasms Hematological Cancers Hematological Malignancies Hematological Neoplasm Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia Acute Myeloid - AML Leukemia, Lymphoid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Lymphatic Diseases Lymphoma Lymphoma Diffuse Large B-cell Lymphoma Non-Hodgkin Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Mental Disorders Multiple Myeloma Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma Myelodysplastic Syndrome Myelodysplastic Syndromes Myeloproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Plasma Cell Paraproteinemias Pathologic Processes Pathological Conditions, Signs and Symptoms Precursor Cell Lymphoblastic Leukemia-Lymphoma Psychological Trauma Stress Disorders, Traumatic Trauma and Stressor Related Disorders Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

General Hospital of Thessaloniki G. Papanikolaou, Thessaloniki, Greece

Loading trial locations.

About this study

Hematological cancers and their treatments can significantly affect the body, social interactions, and psychological health of individuals who experience them. However, such traumatic experiences provide individuals with the opportunity to change and experience what is known as post-traumatic growth. Post-traumatic growth is defined as the positive psychological changes that happen after a traumatic life crisis, and in people with cancer has been connected to biopsychosocial variables like quality of life and biomarkers.

The objectives of this non-pharmacological randomized controlled trial with pre-post measures are implemented in two phases. Phase 1 - Post-traumatic growth intervention: (1) Develop a post-traumatic growth intervention manual, (2) Investigate the feasibility of implementing a post-traumatic growth intervention in the Greek healthcare system, (3) Assess the effectiveness of a psychological intervention in increasing post-traumatic growth and other biopsychosocial variables in people with hematological cancers. Phase 2 - Policy recommendations for the Greek healthcare system: (1) Develop best practice guide on the psychosocial support of people with hematological malignancies in Greece, (2) Develop health policy recommendations on the integration of psychosocial interventions in oncological health care in Greece.

In this context, a systematic review and meta-analysis of the literature on the findings of interventions in the post-traumatic development of people with cancer was conducted and published (https://doi.org/10.1002/pon.6241). The conclusions of the meta-analysis (e.g., components, methods) contributed to the development of an intervention manual (that features education, self-reflection, behavioral activation, connecting and sharing with others, processing and coping with trauma, emotional regulation techniques, and an introduction to mindfulness meditation).

Following this, a pilot study (n = 6) was conducted to assess the feasibility and acceptability of the manual in this setting. Participants also shared their views and experiences of the intervention.

What follows is a randomized controlled trial, recruiting from major hospitals and patient societies. Measurements include questionnaires (e.g., quality of life, anxiety, depression) and biomarkers (CRP, hemoglobin, albumin).

Participants in the experimental group (expected n = 40) will participate in 9 weekly group meetings lasting 120 minutes each, for 6-10 people. Participants in the control group will receive usual care without any intervention (expected n = 40), but will be offered the intervention after the main study is completed. Participants will be assessed at baseline and at follow-up intervals, using self-reported questionnaires, a brief cognitive assessment (namely the Montreal Cognitive Assessment) and biomarkers.

This is one of the first randomized controlled trials in post-traumatic growth for people with hematologic cancers and is expected to contribute to the available evidence-based interventions for people with hematologic cancers through publications in peer-reviewed journals.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Having a diagnosis of a hematological cancer
  • Having completed the planned hospital admission and related treatments
  • Having no more than 5 years since the initial diagnosis

Exclusion criteria

  • Being in active psychological or psychiatric treatment
  • Having an unmanaged mental health difficulty
  • Having a severe cognitive impairment
  • Being unable to give informed consent
  • Being unable to read or speak Greek
  • Having one or more cancer relapses
  • Diagnosed with another type of cancer within 5 years prior to recruitment
  • Having a life expectancy of less than one year

Treatment and study plan

A manualised post-traumatic growth intervention for people with hematological cancers

Behavioral

The intervention consists of nine weekly two-hour group sessions and an optional outdoor activity, delivered over a total period of approximately 2.5 months. Participants will also be encouraged to engage in 30 minutes of daily practice (e.g., reading, writing) related to the intervention content and manual/workbook. The core components of the intervention are summarized by the acronym TRANSFORM: Teach, Reflect, Activate Behavior, Network & Connect, Share, Face & Cope, Open up & Write up, Regulate Emotions, Meditate & Mindfulness. These elements are designed to enhance participants' skills to understand cancer and manage related thoughts, emotions, and behaviors. The intervention is grounded in PTG theory and prior empirical evidence.

Other names: TRANSFORM: Teach, Reflect, Activate Behaviour, Network & Connect, Share, Face & Cope, Open up & Write up, Regulate Emotions, Meditate & Mindfulness, TRANSFORM: Teach, Reflect, Activate Behavior, Network & Connect, Share, Face & Cope, Open up & Write up, Regulate Emotions, Meditate & Mindfulness

Primary outcomes

  1. Posttraumatic Growth Inventory - X (PTGI-X)

    Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.

    PTGI-X is a validated, 25-item, theory-driven questionnaire scored on a 6-point Likert scale, with scores ranging from 0-125, where higher scores indicate higher PTG.

Secondary outcomes

  1. Impact of Event Scale - Revised (IES-R)

    Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.

    The IES-R is a validated 22-item measure of subjective distress of an individual's response to a specific traumatic event. IES-R measures the impact of the trauma over the last 7 days using a 5-item Likert scale. Scores range from 0-99, with higher scores indicating higher impact.

  2. Brief Illness Perceptions Questionnaire (BIPQ)

    Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.

    BIPQ is composed of eight closed questions rated on a 10-point Likert scale, and one open question. The items tap into categories of illness perceptions and how participants understand elements around their illness. Reverse scoring is needed in some questions. Scores range from 0-80, with higher scores indicating worse illness perceptions.

  3. Hospital Anxiety and Depression Scale (HADS)

    Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.

    HADS is a 14-item scale, using a 4-point Likert scale which can be used to measure anxiety and depression, with a higher score indicating higher mental health difficulties. Scores range from 0-21 for each subscale and 0-42 for the total.

  4. Functional Assessment of Chronic Illness Therapy-Spiritual Well-being (FACIT-Sp)

    Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.

    FACIT-Sp is a 12-item measure of QoL and well-being that uses 5-point Likert scales. Accounting for reverse scoring, scores range from 0-48, with higher scores indicating better QoL and well-being.

  5. Montreal Cognitive Assessment (MoCA)

    Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.

    MoCA is an administered cognitive assessment sensitive to mild cognitive changes. Scores range from 0-30, with higher scores indicating better cognitive function.

  6. Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu)

    Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.

    FACT-Leu is a 44-item quality of life disease-specific measure. Accounting for reverse scoring, scores range from 0-176 with higher scores indicating better quality of life.

  7. Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)

    Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.

    FACT-Lym is a 42-item quality of life disease-specific measure. Accounting for reverse scoring, scores range from 0-168, with higher scores indicating better quality of life.

  8. Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT)

    Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.

    FACT-BMT is a 50-item quality of life disease-specific measure, scoring between 0-200. Accounting for reverse scoring, higher scores indicate better quality of life.

  9. Biomarkers

    Time frame: Pre-intervention (baseline), post-intervention (9 weeks post-baseline), and approximately at 3, 6, and 12 months following the post-intervention assessment.

    (1) Hemoglobin is a protein in red blood cells that transports oxygen or carbon dioxide from the lungs to tissues and back. (2) C-reactive protein (CRP) is a protein produced in response to inflammation which is a sensitive but non-specific marker of acute inflammation, infection, or tissue injury. (3) Albumin is a plasma protein, synthesized by the liver, maintaining oncotic pressure and transporting hormones, drugs, and ions.

Sponsors and collaborators

Lead sponsor

University of West Attica

Other

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Sep 10, 2026
Registry last updated
Sep 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.